Keyphrases
Chemokine Expression
100%
Lipopolysaccharide
100%
Sickness Behavior
100%
Lipopolysaccharide-induced
100%
Expression Activity
100%
CXCL10
40%
Chemokine (C-C motif) Ligand 2 (CCL2)
40%
Naltrexone
30%
Inflammation
20%
μ-opioid Receptor
20%
Neuroinflammation
20%
Inflammatory Pathways
20%
Protective Effect
20%
Opioid Antagonist
10%
Neurodegenerative Diseases
10%
Mechanism of Action
10%
Attenuation
10%
Astrocytes
10%
Neurological Conditions
10%
Astroglial Cells
10%
Neuroprotective Effect
10%
Open Field Test
10%
Anti-inflammatory Effect
10%
Monocyte Chemoattractant protein-1 (MCP-1)
10%
β-funaltrexamine
10%
Bacterial Lipopolysaccharide
10%
C57BL
10%
Enzyme-linked Immunosorbent Assay (ELISA)
10%
Non-selective
10%
Mu-opioid Receptor Antagonist
10%
Psychiatric Disorders
10%
Inflammatory Chemokines
10%
Neuroprotection
10%
In Vivo Experiment
10%
Dosing Schedule
10%
Two-way Analysis of Variance
10%
Behavioral Deficits
10%
Behavioural Expression
10%
Interferon-induced Protein
10%
Neuroscience
Chemokine
100%
Lipopolysaccharide
100%
Sickness Behavior
100%
CXCL10
30%
CCL2
30%
Naltrexone
23%
μ-Opioid Receptor
23%
Blood Plasma
23%
In Vivo
15%
In Vitro
15%
Anti-Inflammatory
15%
Narcotic Antagonist
15%
Astrocyte
7%
Interferon
7%
Monocyte Chemotactic Protein 1
7%
Neuroprotective Agent
7%
Bacterium Lipopolysaccharide
7%
Neurodegeneration
7%
Neuroprotection
7%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Chemokine
100%
Lipopolysaccharide
100%
Naltrexone
23%
Anti-Inflammatory Drug
15%
Inflammation
15%
Nervous System Inflammation
15%
μ-Opioid Receptor
15%
Infection
7%
Interferon
7%
Mu Opiate Receptor Antagonist
7%
Enzyme-Linked Immunosorbent Assay
7%
Neuroprotective Agent
7%
Bacterium Lipopolysaccharide
7%
Neuroprotection
7%
C57BL 6 Mouse
7%
Nerve Degeneration
7%
Beta Funaltrexamine
7%
Monocyte Chemotactic Protein 1
7%
Narcotic Antagonist
7%